What is the regulatory status of Semax (Intranasal)?

Semax (Intranasal) regulatory status: Unapproved (Russia approved) in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the standard dosing protocol for Semax (Intranasal)?

Conventional Semax (Intranasal) dosing is 300-1000 mcg per dose 2-4x daily for 10-14 day courses via intranasal. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What are the safety considerations for Semax (Intranasal)?

Excellent. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Semax (Intranasal)'s CNS effect hours pharmacokinetic profile and intranasal administration route influence the side-effect profile in predictable ways.

Should I cycle Semax (Intranasal)?

Standard cycle for Semax (Intranasal) is 8–12 weeks of 2-4x daily for 10-14 day courses 300-1000 mcg per dose dosing via intranasal, followed by a 4 week complete off-period. The off-period is calibrated to Semax (Intranasal)'s CNS effect hours half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What does Semax (Intranasal) stack well with?

For protocol / scheduling / cycling protocols, Semax (Intranasal) pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from Semax (Intranasal)'s primary mechanism (Same Semax; olfactory delivery preferred), producing additive or synergistic effects rather than receptor competition.

Home/ Compounds/ Semax (Intranasal)

Semax (Intranasal)

Protocol

For protocol designers building Semax (Intranasal) into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 300-1000 mcg per dose 2-4x daily for 10-14 day courses dose at CNS effect hours half-life informs which scheduling pattern fits.

Protocol / Scheduling / Cycling Applications

Cycle LengthWeekly TimingPeriodised CyclesOff-TimeStack Scheduling

Key Takeaways

Scheduling lens: Semax (Intranasal)'s CNS effect hours half-life via intranasal places it in the multi-daily-dosing bucket.
Mechanism: Same Semax; olfactory delivery preferred.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Same Semax; olfactory delivery preferred. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Semax (Intranasal).

Cycle length and off-cycle planning

Standard Semax (Intranasal) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Semax (Intranasal) protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Semax (Intranasal) schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

Semax (Intranasal) with a CNS effect hours half-life pharmacokinetic profile sits in the multiple-daily-dosing bucket. The schedule is best built around either 2-4x daily for 10-14 day courses, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Travel Considerations

For travel considerations scheduling, Semax (Intranasal) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Weekly Timing

The most-asked scheduling question for Semax (Intranasal) in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Off-Time

Schedule design for Semax (Intranasal) in off-time starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Wash-Out

For wash-out scheduling, Semax (Intranasal) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300-1000 mcg per dose	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180-1000 mcg per dose	4–6 weeks initial cycle
Protocol focus	Intranasal	300-1000 mcg per dose	2-4x daily for 10-14 day courses
Maintenance phase	Intranasal	210-1000 mcg per dose	Ongoing with periodic pauses

Dose timing for Semax (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semax (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Semax (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Semax (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
Semax (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Semax (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
Semax (Intranasal) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Semax (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.
Semax (Intranasal) + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Semax (Intranasal)'s mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent.

Lens-specific safety considerations for protocol / scheduling / cycling use of Semax (Intranasal): Excellent. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Semax in stroke recovery

PMID 21643748

Semax (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Semax (Intranasal)	ACTH-derived nootropic heptapeptide (intranasal)	CNS effect hours	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

Daily timing for Semax (Intranasal)?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

How does Semax (Intranasal)'s half-life affect dosing?

Semax (Intranasal) has a plasma half-life of CNS effect hours, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-4x daily for 10-14 day courses dosing at 300-1000 mcg per dose per dose explains the typical onset timeline for scheduling and cycle endpoints.

How long until I see results from Semax (Intranasal)?

Acute effects from Semax (Intranasal) appear within hours of dosing for receptor-level changes. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a Semax (Intranasal) Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Semax (Intranasal) and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 813 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semax (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Semax (Intranasal)

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised